Production (Stage)
PMV Pharmaceuticals, Inc.
PMVP
$0.97
$0.022.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -18.11% | 106.54% | -18.22% | -11.74% | -21.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.38% | 33.15% | 11.51% | 0.24% | -17.97% |
| Operating Income | -22.38% | -33.15% | -11.51% | -0.24% | 17.97% |
| Income Before Tax | -28.57% | -45.97% | -15.10% | 0.26% | 20.17% |
| Income Tax Expenses | -- | 100.00% | -- | -404,425.00% | -- |
| Earnings from Continuing Operations | -14.18% | -45.98% | -15.54% | 93.04% | 20.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.18% | -45.98% | -15.54% | 93.04% | 20.17% |
| EBIT | -22.38% | -33.15% | -11.51% | -0.24% | 17.97% |
| EBITDA | -24.73% | -35.52% | -11.66% | -0.23% | 19.01% |
| EPS Basic | -13.07% | -44.78% | -9.87% | 93.80% | 28.98% |
| Normalized Basic EPS | -32.55% | -44.78% | -9.48% | 11.23% | 31.78% |
| EPS Diluted | -13.07% | -44.78% | -9.87% | 93.80% | 28.98% |
| Normalized Diluted EPS | -32.55% | -44.78% | -9.48% | 11.23% | 31.78% |
| Average Basic Shares Outstanding | 0.98% | 0.83% | 5.15% | 12.37% | 12.39% |
| Average Diluted Shares Outstanding | 0.98% | 0.83% | 5.15% | 12.37% | 12.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |